You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海思科(002653.SZ)與Starton簽訂奧氮平透皮貼劑合作協議
格隆匯 03-01 15:56

格隆匯 3 月 1日丨海思科(002653.SZ)公佈,公司近日與美國Starton Therapeutics Inc.(“Starton”)簽訂了關於奧氮平透皮貼劑(“STAR-OLZ”)的《Developmentand Commercial License Agreement》。

Starton授予海思科其在研的每週一次奧氮平透皮給藥系統、擬用於腫瘤化療引發的噁心嘔吐產品STAR-OLZ在中國大陸區域開發、註冊和商業化STAR-OLZ的獨家權利。

交易總對價為 750萬美元,包括現金預付款及潛在開發和註冊里程碑付款。此外,如該產品成功在中國大陸區域獲批上市,海思科將根據該項目在中國大陸的年度淨銷售額向Starton支付一定的特許權使用費。

Starton(www.startontx.com)的目標是通過安全有效地開發基於當前治療模式的產品,對癌症患者的生活產生積極影響。該公司是一家臨牀階段的生物科技公司,致力於改變現有護理療法的標準。公司專注於透皮貼,篩選已批准多年的暢銷藥物,在其豐富的臨牀使用基礎和數據上,開發新的劑型或新的適應症,通過505(b)2的申報途徑,降低藥物開發時間和開發風險。

公司在腫瘤嘔吐領域已深耕數年,成功開發並且商業化包括甲磺酸多拉司瓊注射液和鹽酸帕洛諾司瓊注射液在內的預防噁心嘔吐的產品。目前,兩個產品在腫瘤嘔吐領域已佔領相當的市場份額。

此次引進STAR-OLZ將有望進一步完善豐富公司在腫瘤止吐領域的產品線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account